LPA (lysophosphatidic acid), the simplest of al glycerophospholipids, is a potent inducer of cell proliferation, migration and survival. It does so by activating its cognate G-protein-coupled receptors, four of which have been identified. LPA receptors couple to at least three distinct G-proteins and thereby activate multiple signal transduction pathways, particularly those initiated by the small GTPases Ras, Rho and Rac. Our recent work has shown that LPA signals Rac activation via the Tiam1 GDP/GTP exchange factor and thereby stimulates cell migration. Here we discuss recent progress in our understanding of LPA action.
Introduction
Although LPA (lysophosphatidic acid) was initially characterized on the basis of its growth-factor activities, the list of documented cellular responses to LPA has grown considerably since then and now also includes stimulation of cell migration and survival as well as neurite remodelling, increase in endothelial permeability and inhibition of gapjunctional communication [1] (Table 1) . This remarkable diversity of responses is explained by the fact that LPA receptors signal via at least three distinct G-protein subfamilies and their multiple downstream effectors. Thus LPA not only acts via classic second messenger pathways, it also activates Ras-and Rho-family GTPases, which control cell proliferation, migration and morphogenesis, respectively.
Not surprisingly for a platelet-produced growth factor, LPA is a potent inducer of wound healing: it stimulates the proliferation and migration of mesenchymal and epithelial cells, and it shows vasoconstrictive actions and enhances the production of matrix metalloproteases, which all are important events in tissue repair. Topically applied LPA promotes wound healing in skin [2] , while rectally applied LPA stimulates intestinal epithelial wound healing and diminishes mucosal damage in rats [3] . LPA may also promote wound healing in the upper digestive organs, as it is present in saliva and is mitogenic for epithelial cells derived from tongue, oesophagus and larynx [4] .
LPA receptors
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transmembrane-domain receptors. Candidate high-affinity LPA receptors (38-40 kDa; estimated K d ≈ 10 nM) were initially detected by photo-affinity labelling experiments [5] . Yet it took several more years before the first cDNA encoding a functional LPA receptor was identified (LPA 1 ; previously Edg-2 or vzg-1) [6] , followed by the identification of two related LPA receptors, LPA 2 and LPA 3 (previously Edg-4 and Edg-7 respectively) [7] , and of five additional Edg family members that encode receptors for the lysophospholipid sphingosine 1-phosphate [8] . The recent identification of a fourth LPA-specific receptor (LPA 4 /GPR23/P2Y9), which is closely related to purinergic P2Y receptors but far distant from the Edg receptors [9] , suggests that LPA receptors have evolved from at least two distinct ancestor genes. LPA 1 is the most widely expressed and best-characterized subtype, whereas LPA 2 and LPA 3 have a somewhat more restricted distribution pattern [7] . Preliminary evidence suggests that LPA 4 is expressed at significant levels in ovary when compared with other human tissues [9] .
The three LPA receptors of the Edg family (LPA 1 , LPA 2 and LPA 3 ) show about 50% sequence similarity to one another, with their C-terminal tails being most divergent. In common with nearly all GPCRs, the LPA 1 receptor undergoes rapid ligand-induced internalization from the plasma membrane [10, 11] , but mechanistic details and the metabolic fate of the internalized receptor (degradation or recycling) remain to be elucidated.
Signalling pathways
LPA receptors can couple to at least three distinct Gprotein subfamilies, notably G q/11 , G i/o and G 12/13 [1] . The major signalling routes include: (i) G q -(or G i -) mediated stimulation of phospholipase C with subsequent PtdInsP 2 hydrolysis; (ii) G i -mediated inhibition of adenylate cyclase with a subsequent fall in cAMP levels; (iii) G i -mediated stimulation of the mitogenic Ras/mitogen-activated protein kinase cascade; (iv) Gα 12/13 -mediated activation the small GTPase RhoA, which regulates cytoskeletal contraction, Hepatoma cells, fibroblasts [50] accompanied by chloride-mediated membrane depolarization (Gα 13 -mediated); (v) G i -mediated activation of PI 3-kinase (phosphoinositide 3-kinase) leading to activation of Rac and forward cell movement (see below), and to protein kinase B/Akt, which promotes cell survival.
Ras/mitogen-activated protein kinase activation
LPA is among the prototypic GPCR ligands that activate Ras and the downstream mitogen-activated protein kinase cascade via pertussis toxin-sensitive G i in a tyrosine kinasedependent manner [12, 13] . The literature on how G i couples to Ras activation is confusing, however, and it seems safe to conclude that there is no unequivocal pathway of G i → tyrosine kinase → Ras-GTP accumulation [14, 15] . The difficulty is that Ras regulation is much more complex than originally anticipated, as it involves multiple GDP/GTPexchange factors and GTPase-activating proteins acting in a mutually opposing and cell-type-dependent manner. LPA often synergizes with EGF (epidermal growth factor) in stimulating cell proliferation [16, 17] , but positive cross-talk between LPA and EGF signalling cascades can occur at numerous levels, not necessarily involving receptor transactivation.
In human A431 carcinoma cells, on the other hand, LPA (and other lysolipids) can antagonize EGF action by inducing rapid internalization of EGF receptors from the cell surface, without evidence for concurrent EGF receptor transactivation [18] . Although mechanistically poorly understood, lysophospholipid-induced down-regulation of EGF receptors may provide a tool to block EGF signalling in cancer cells.
Rho and Rac activation
LPA is well known for its striking effects on cytoskeletal organization and cell shape. The cytoskeleton is regulated by the Rho-GTPases RhoA, Cdc42 and Rac, the master switches that also influence transcription [19] . Specifically, RhoA mediates actomyosin-driven contractility, Cdc42 controls filopodium formation, whereas Rac regulates lamellipodium protrusion and drives forward cell movement. The mechanism by which LPA activates RhoA is reasonably well understood. RhoA activation proceeds via Gα 12/13 subunits [20] which bind directly to at least three distinct RhoGEFs (Rho-specific guanine nucleotide-exchange factors) that promote RhoA-GTP accumulation [21] . This then leads to activation of Rho kinase, which in turn results in actomyosin-based contractile events such a neurite retraction, cell rounding and endothelial tight junction opening [22] [23] [24] .
Our recent work shows that LPA, acting via LPA 1 receptors, also activates Rac and thereby promotes cell (re)spreading (following initial rounding), lamellipodium formation and cell migration [10] . Rac activation is inhibited by pertussis toxin and depends on PI 3-kinase activity, most probably the Gβγ-regulated PI 3-kinase β isoform [10] . Through diverse complementary approaches, it was established that the Rac-specific guanine nucleotide-exchange factor Tiam1 is responsible for Rac activation by LPA. Tiam1 was originally isolated as a lymphoma invasioninducing gene product and has been implicated in tumour cell invasion, neurite outgrowth and cell-cell adhesion [25, 26] . In the simplest signalling scheme compatible with the available data, Tiam1 is activated by direct binding of PI 3-kinase lipid products [PtdIns(3,4,5)P 3 ] to its N-terminal PH (pleckstrin homology) domain, although it remains possible that additional signals emanating from G i are required for full activation of Tiam1 [10] .
It is of note that that Tiam1-deficient fibroblasts show enhanced RhoA activation, stress fibre formation and cell rounding in response to LPA [10] , consistent with activated Rac inhibiting RhoA. The mechanism underlying this inhibitory cross-talk between Rac and RhoA is currently not known.
LPA production by secreted phospholipases
How does bioactive LPA normally accumulate in the extracellular environment? A major LPA production pathway involves secreted PLD (phospholipase D). A prototypic bacterial exo-PLD (from Streptomyces chromofuscus) can generate LPA in the outer leaflet of the plasma membrane through hydrolysis of pre-existing LPC (lysophosphatidylcholine) with consequent induction of LPA receptor signalling pathways, cytoskeletal contraction and DNA synthesis [27] . These results raise the question of whether LPA-producing exo-PLDs also exist in mammals. In the mid-1980s, Tokumura [28] detected a lysoPLD activity in rat plasma that converts exogenously added LPC into LPA. Plasma lysoPLD contributes to LPA production following platelet activation [29] , but the enzyme was not identified until recently when it was found to be identical to a known exo-enzyme, named ATX (autotaxin) [30, 31] .
ATX, a 125 kDa glycoprotein, was identified in the early 1990s as an autocrine motility factor that stimulates melanoma cell migration in a pertussis toxin-sensitive manner and belongs to the family of ecto-NPPs (ecto-nucleotide pyrophosphatase/phosphodiesterases) [32, 33] . Its precise biochemical function has been elusive, however. The NPP family comprises at least three ecto-enzymes capable of hydrolysing phosphodiester and pyrophosphate bonds in various nucleotides [34, 35] . ATX/NPP2 and its family members are type-II transmembrane proteins with a very short N-terminal cytosolic part, a single transmembrane domain, two cysteine-rich somatomedin B-like domains possibly involved in dimerization, and a large catalytic ectodomain [34, 35] . Soluble ATX is derived from the full-length form by membrane-proximal proteolytic cleavage.
There were previously no indications that any of the NPP members could function as a (lyso)PLD because their sequence lacks the conserved motifs that characterize the PLD superfamily. Instead, ATX was hypothesized to act by influencing ecto-nucleotide metabolism or recycling. A recent study shows, however, that ATX/NPP2 has relatively little nucleotide-hydrolysing activity when compared with NPP1 and NPP3; conversely, the NPP1 and NPP3 enzymes lack detectable lysoPLD activity [36] , which is surprising because the catalytic sites of NPP1-3 are highly conserved. It thus appears that ATX/NPP2 is a unique LPA-generating lysoPLD, with no functional redundancy within the ecto-NPP family.
ATX/lysoPLD is widely expressed, with highest mRNA levels found in brain, ovary, lung, intestine and kidney. The tissue origin of circulating plasma ATX/lysoPLD is unknown, but the liver and vascular endothelium are obvious candidates. A causal link between ATX and tumour progression has emerged from studies in nude mice, where injection of ATX-overexpressing Ras-transformed 3T3 cells enhances tumour aggressiveness [37] and Matrigel plug assays show that ATX can promote tumour angiogenesis [38] . Through local production of LPA, ATX may provide an invasive microenvironment for tumour cells and thus contribute to metastasis.
The biological outcome of ATX/lysoPLD action will depend on the local availability of its substrates. The major lysophospholipid substrate for ATX/lysoPLD is LPC. LPC is secreted by the liver and is abundantly present in plasma, where it is predominantly bound to albumin and, to a lesser extent, lipoproteins [39] . One would predict that ATX/lysoPLD can also hydrolyse the lysophospholipid sphingosylphosphorylcholine, to generate bioactive sphingosine 1-phosphate. However, serum sphingosylphosphorylcholine levels (≈100 nM) [40] are three orders of magnitude lower than those of LPC. It therefore is currently unclear to what extent sphingosylphosphorylcholine serves as a physiologically relevant substrate for ATX/lysoPLD.
Concluding remarks
Since most mammalian cell types show pleiotropic responses to LPA, it seems likely that this lipid mediator performs a signalling role in nearly all tissues and systems of the body. Ongoing studies will further clarify the details of LPA receptor signalling cascades and their biological sigificance. Identification of the biological activities of LPA in vivo has only recently begun, and considerably more work is required to understand LPA's role in health and disease.
One priority is to delineate the regulation of extracellular LPA levels by ATX/lysoPLD and other lipid-metabolizing enzymes such as the LPPs (lipid phosphate phosphohydrolases). The discovery that soluble ATX is identical to plasma lysoPLD is an exciting development, since it not only underscores the importance of the autocrine/paracrine production of LPA in tumour progression, but also links previously unconnected areas of cell biology.
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